CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Trillium Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Trillium Therapeutics Inc
2488 Dunwin Dr
Phone: (416) 595-0627p:416 595-0627 MISSISSAUGA, ON  L5L 1J9  Canada Fax: (416) 595-0627f:416 595-0627

This company was Merged or Acquired on 11/17/2021.
This company ceased filing statements with the SEC on 11/29/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPaFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPa as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202112/31/2020YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Director DeborahBaron 11/17/2021 11/17/2021
Senior Vice President - Corporate Development and Strategy RosemaryHarrison 38 1/1/2021 11/5/2020
Vice President, Director AndrewMuratore 11/17/2021 11/17/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Fluorinov Pharma Inc.
TR
TRIL
Trillium Therapeutics Inc.
Trillium Therapeutics USA Inc.

General Information
Number of Employees: 33 (As of 12/31/2020)
Outstanding Shares: 111,745,125 (As of 10/24/2021)
Stock Exchange: TSE
Fax Number: (416) 595-0627


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, July 4, 2024